A Multifactorial Risk Score System for the Prediction of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus

References

• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9 (th) editions. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316(6):602–610. doi:10.1001/jama.2016.10924
   PubMed Web of Science ®Google Scholar
• Zhang XX, Kong J, Yun K. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies. J Diabetes Res. 2020;3:2315607.
   Google Scholar
• Cheng HT, Xu X, Lim PS, et al. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015. Diabetes Care. 2021;44(1):89–97. doi:10.2337/dc20-1913
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. doi:10.2215/CJN.11491116
   PubMed Web of Science ®Google Scholar
• Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):260–266. doi:10.1053/j.ackd.2014.03.009
   PubMed Web of Science ®Google Scholar
• Radcliffe NJ, Seah JM, Clarke M, et al. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8(1):6–18. doi:10.1111/jdi.12533
   PubMed Web of Science ®Google Scholar
• Maclsaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. AM J Kidney Dis. 2014;63(Suppl 2):S39–62. doi:10.1053/j.ajkd.2013.10.048
   PubMed Web of Science ®Google Scholar
• Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172(10):761–769. doi:10.1001/archinternmed.2011.2230
   PubMedGoogle Scholar
• Oellgaard J, Gæde P, Rossing P, et al. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017;91(4):982–988. doi:10.1016/j.kint.2016.11.023
   PubMed Web of Science ®Google Scholar
• Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomized controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951–964. doi:10.1016/S2213-8587(17)30327-3
   PubMed Web of Science ®Google Scholar
• Ueki K, Sasako T, Okazaki Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021;99(1):256–266. doi:10.1016/j.kint.2020.08.012
   PubMed Web of Science ®Google Scholar
• Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1–73. doi:10.7326/M14-0698
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a who consultation. part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• KDOQI; KDOQI Clinical practice Guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154. doi:10.1053/j.ajkd.2006.12.005
   PubMed Web of Science ®Google Scholar
• Liu LS. Writing group of Chinese guidelines for the management of hypertension: [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(7):579–615.
   PubMedGoogle Scholar
• Sullivan LM, Massaro JM, D’Agostino RB. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med. 2004;23(10):1631–1660. doi:10.1002/sim.1742
   PubMed Web of Science ®Google Scholar
• Jiang WH, Wang JY, Shen XF, et al. Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and meta-analysis of 20 cohorts. Diabetes Care. 2020;43(4):925–933. doi:10.2337/dc19-1897
   PubMed Web of Science ®Google Scholar
• Fagerudd JA, Tarnow L, Jacobsen P, et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes. 1998;47(3):439–444. doi:10.2337/diabetes.47.3.439
   PubMed Web of Science ®Google Scholar
• Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis. 2011;18(1):28–41. doi:10.1053/j.ackd.2010.10.003
   PubMed Web of Science ®Google Scholar
• Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017;6(6):CD010137. doi:10.1002/14651858.CD010137.pub2
   PubMedGoogle Scholar
• Brunskill NJ. C-peptide and diabetic kidney disease. J Intern Med. 2017;281(1):41–51. doi:10.1111/joim.12548
   PubMed Web of Science ®Google Scholar
• Huang YJ, Wang YH, Liu CF, et al. C‐peptide, glycaemic control, and diabetic complications in type 2 diabetes mellitus: a real‐world study. Diabetes Metab Res Rev. 2022;38(4):e3514. doi:10.1002/dmrr.3514
   PubMed Web of Science ®Google Scholar
• Yamout H, Lazich I, Bakris GL. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):281–286. doi:10.1053/j.ackd.2014.03.005
   PubMed Web of Science ®Google Scholar
• Eid S, Sas KM, Abcouwer SF, et al. New insights into the Mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019;62(9):1539–1549. doi:10.1007/s00125-019-4959-1
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Laffe L, Lynch J, et al. Elevated serum uric acid is associated with greater risk for hypertension and diabetic kidney diseases in obese adolescents with type 2 diabetes: an observational analysis from the treatment options for type 2 diabetes in adolescents and youth (TODAY) study. Diabetes Care. 2019;42(6):1120–1128. doi:10.2337/dc18-2147
   PubMed Web of Science ®Google Scholar
• Wang J, Li H, Tan M, et al. Association between thyroid function and diabetic nephropathy in euthyroid subjects with type 2 diabetes mellitus: a cross-sectional study in China. Oncotarget. 2019;10(2):88–97. doi:10.18632/oncotarget.26265
   PubMedGoogle Scholar
• Feng X, Huang J, Peng Y, et al. Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease. BMC Endocr Disord. 2021;21(1):108–116. doi:10.1186/s12902-020-00672-8
   PubMed Web of Science ®Google Scholar
• Pan LL, Ye YL, Wo MY, et al. Clinical significance of hemostatic parameters in the prediction for type 2 diabetes mellitus and diabetic nephropathy. Dis Markers. 2018;2018:5214376. doi:10.1155/2018/5214376
   PubMed Web of Science ®Google Scholar
• Hess K. The vulnerable blood. Coagulation and clot structure in diabetes mellitus. Hamostaseplogie. 2015;35(1):25–3329. doi:10.5482/HAMO-14-09-0039
   Web of Science ®Google Scholar
• Kunutsor SK, Abbasi A, Adler AI. Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. Ann Epidemiol. 2014;24(4):809–816. doi:10.1016/j.annepidem.2014.09.001
   PubMedGoogle Scholar
• Brennan PN, Dillon JF, Tapper LB. Gamma--glutamyl-transferase-(γ-GGT) ——an old dog with new tricks? Liver Int. 2022;42(1):9–15. doi:10.1111/liv.15099
   PubMed Web of Science ®Google Scholar
• Li SQ, Liao XL, Pan YS, et al. Gamma-glutamyl transferase levels are associated with the occurrence of post-stroke cognitive impairment: a multicenter cohort study. BMC Neurol. 2022;22(1):65. doi:10.1186/s12883-022-02587-4
   PubMed Web of Science ®Google Scholar
• Zhang J, Deng YY, Wan Y, et al. Association between serum albumin level and microvascular complications of type 2 diabetes mellitus. Diabetes Metab Syndr Obe. 2022;15:2173–2182. doi:10.2147/DMSO.S373160
   PubMed Web of Science ®Google Scholar